XBP1 and acute myeloid leukemia: HNA (2-hydroxy-1-naphthaldehyde), toyocamycin (an adenosine analog produced by Actinomycetes), and 3ETH (3-ethoxy-5,6-dibromosalicylaldehyde) suppressed XBP1 mRNA splicing in acute myeloid leukemia cells, followed by caspase-dependent apoptosis, G1 cell cycle arrest, and altered expression of chaperones, Bcl-2 family, G1 phase-controlling proteins, and miR-34a, whereas its synergic effect with bortezomib was linked with p-JNK and p-PI3K [83].